METASTATIC PANCREATIC NEUROENDOCRINE TUMOR
Clinical trials for METASTATIC PANCREATIC NEUROENDOCRINE TUMOR explained in plain language.
Never miss a new study
Get alerted when new METASTATIC PANCREATIC NEUROENDOCRINE TUMOR trials appear
Sign up with your email to follow new studies for METASTATIC PANCREATIC NEUROENDOCRINE TUMOR, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo targets Hard-to-Treat pancreatic tumors
Disease control Recruiting nowThis early-phase trial is testing whether combining two targeted therapies—sunitinib malate and Lutathera—is safe for people with advanced pancreatic neuroendocrine tumors that have spread or cannot be removed. Sunitinib blocks signals that help tumors grow, while Lutathera deliv…
Matched conditions: METASTATIC PANCREATIC NEUROENDOCRINE TUMOR
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New combo therapy aims to boost tumor control in pancreatic cancer
Disease control Recruiting nowThis early-phase study tests whether adding the drug fulvestrant to standard radiation therapy (Lu-DOTATATE) is safe and helps shrink tumors in people with advanced pancreatic neuroendocrine tumors. About 25 adults whose cancer has spread or cannot be removed by surgery will take…
Matched conditions: METASTATIC PANCREATIC NEUROENDOCRINE TUMOR
Phase: PHASE1 • Sponsor: University of Chicago • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC